The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine‐expressing myeloma cells

Summary We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine ‐ a lipid normally confined to the intracellular sid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2017-05, Vol.177 (3), p.423-440
Hauptverfasser: Vuckovic, Slavica, Vandyke, Kate, Rickards, David A., McCauley Winter, Padraig, Brown, Simon H. J., Mitchell, Todd W., Liu, Jun, Lu, Jun, Askenase, Philip W., Yuriev, Elizabeth, Capuano, Ben, Ramsland, Paul A., Hill, Geoffrey R., Zannettino, Andrew C. W., Hutchinson, Andrew T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine ‐ a lipid normally confined to the intracellular side of the cell membrane. However, interestingly, phosphatidylserine was expressed on the surface of all myeloma cell lines tested (n = 12) and 9/15 primary myeloma samples. Notably, the level of phosphatidylserine expression correlated well with sensitivity to GW4869. Inhibition of cell surface phosphatidylserine exposure with brefeldin A resulted in resistance to GW4869. Finally, GW4869 was shown to delay the growth of phosphatidylserine‐high myeloma cells in vivo. To the best of our knowledge, this is the first example of using a small molecule to target phosphatidylserine on malignant cells. This study may provide the rationale for the development of phosphatidylserine‐targeting small molecules for the treatment of surface phosphatidylserine‐expressing cancers.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.14561